Waldencast plc Dossier
Qualitative Analysis
Business overview
Waldencast plc (NASDAQ: WALD) is a global multi-brand beauty and wellness platform founded by Michel Brousset and Hind Sebti. The company operates with a brand-led business model designed to acquire, accelerate, and scale conscious, high-growth, purpose-driven brands. Historically, its operations have been structured around two primary segments: Obagi Medical, a science-backed, medical-grade skincare and aesthetics brand, and Milk Makeup, a clean, vegan, and cruelty-free cosmetics brand. However, in June 2026, Waldencast announced a definitive agreement to sell Obagi Medical to private equity firm Bridgepoint for up to $460 million. Following the close of this transaction (expected in Q3 2026), Milk Makeup will remain Waldencast's sole operating beauty brand.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Divesting the Obagi Medical business to Bridgepoint Group to address balance sheet constraints and eliminate approximately $178 million of senior secured term loan debt.
Expected impact: Significantly reduces net debt and financial leverage, simplifying the corporate structure.
Concentrating all operational resources, marketing investments, and management focus on accelerating the global growth of Milk Makeup as a leading color cosmetics brand.
Expected impact: Enables a sharper strategic focus on Milk Makeup's global growth potential under the leadership of President and Co-Founder Mazdack Rassi.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of Novaestiq and the U.S. rights to the Saypha line of hyaluronic acid injectable gels to expand Obagi Medical's addressable market into the U.S. dermal filler market.
Financial impact: Doubled Obagi Medical's addressable market potential in the U.S. and led to the Q1 2026 launch of the FDA-approved Obagi Saypha MagIQ dermal filler line.
Strategic Partnerships
Waldencast entered into a definitive agreement to sell Obagi Medical to Bridgepoint for up to $460 million, with Waldencast co-founders transitioning to lead Obagi under Bridgepoint.
Terms: Up to $460 million total value, consisting of $366 million in cash at closing, $30 million in vendor notes, and up to $64 million in earnout payments linked to 2026 and 2027 revenue milestones.